BR0314195A - Substituted Pyridine Derivatives as Antitumor Agents - Google Patents

Substituted Pyridine Derivatives as Antitumor Agents

Info

Publication number
BR0314195A
BR0314195A BR0314195-0A BR0314195A BR0314195A BR 0314195 A BR0314195 A BR 0314195A BR 0314195 A BR0314195 A BR 0314195A BR 0314195 A BR0314195 A BR 0314195A
Authority
BR
Brazil
Prior art keywords
pyridine derivatives
substituted pyridine
antitumor agents
agents
antitumor
Prior art date
Application number
BR0314195-0A
Other languages
Portuguese (pt)
Inventor
Mauro Angiolini
Maria Menichincheri
Domenico Fusar Bassini
Markus Gude
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0314195A publication Critical patent/BR0314195A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE PIRIDINA SUBSTITUìDA COMO AGENTES ANTITUMORAIS". A presente invenção refere-se a novos derivados de piridina substituída, ativos como inibidores de telomerase, seu uso como agentes terapêuticos, particularmente como agentes antitumorais, um processo para a sua preparação, e composições farmacêuticas que os compreendem."PYRIDINE DERIVATIVES REPLACED AS ANTI-TUMOR AGENTS". The present invention relates to novel substituted pyridine derivatives active as telomerase inhibitors, their use as therapeutic agents, particularly as antitumor agents, a process for their preparation, and pharmaceutical compositions comprising them.

BR0314195-0A 2002-09-10 2003-08-26 Substituted Pyridine Derivatives as Antitumor Agents BR0314195A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40947102P 2002-09-10 2002-09-10
PCT/EP2003/009572 WO2004024711A1 (en) 2002-09-10 2003-08-26 Substituted pyridine derivatives as antitumor agent

Publications (1)

Publication Number Publication Date
BR0314195A true BR0314195A (en) 2005-07-26

Family

ID=31993972

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314195-0A BR0314195A (en) 2002-09-10 2003-08-26 Substituted Pyridine Derivatives as Antitumor Agents

Country Status (7)

Country Link
EP (1) EP1546129A1 (en)
JP (1) JP2006503028A (en)
AU (1) AU2003260472A1 (en)
BR (1) BR0314195A (en)
CA (1) CA2498281A1 (en)
MX (1) MXPA05001883A (en)
WO (1) WO2004024711A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013180A1 (en) 2006-04-19 2009-01-14 Laboratoires Serono SA Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors
EP2144877A1 (en) * 2007-04-04 2010-01-20 UCB Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
EA014100B1 (en) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" 2,4-diaminopyridine derivatives, pharmaceutical composition, medicament based thereon for treating and preventing diseases and disorders caused by nmda-receptors hyperactivation and/or as stimulators of cognitive function and method of treatment
CN108084155A (en) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 SSAO inhibitor of methyl adamantane and alcoxyl pyridine structure and application thereof
CN107935993A (en) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 Methyl adamantane and nitropyridine structural derivative, Its Preparation Method And Use
CN107935992A (en) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 One kind contains adamantane and haloperidid structural compounds and purposes
CN109988147A (en) * 2017-12-29 2019-07-09 佛山汉方中医医院有限公司 SSAO inhibitor, preparation method and its usage containing adamantane structure
CN108033945A (en) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 A kind of adamantane and nitropyridine structural compounds and purposes
CN107935990A (en) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 Containing adamantane and alcoxyl pyridine structure compound, preparation method and the usage
CN107935989A (en) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 Adamantane and itrile group pyridine structure compound, preparation method and the usage
CN108191823A (en) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 A kind of alkyl substitution adamantane SSAO inhibitor, preparation method and its usage
CN107935991A (en) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 A kind of methyl adamantane and amido pyridine structure derivative, Its Preparation Method And Use
CN108191825A (en) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 A kind of methyl adamantane and nitropyridine structural derivative and application thereof
CN108191824A (en) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 A kind of methyl adamantane and dimethylaminopyridine structural derivative, Its Preparation Method And Use
CN107915719A (en) * 2017-12-29 2018-04-17 佛山汉方中医医院有限公司 SSAO inhibitor of a kind of methyl adamantane and pyridine structure and application thereof
CN108033946A (en) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 A kind of SSAO inhibitor, preparation method and its usage containing adamantane structure
CN108129457A (en) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 A kind of adamantane SSAO inhibitor, preparation method and its usage
CN108084154A (en) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 A kind of adamantane and amido pyridine structure derivative, preparation method and the usage
CN108129458A (en) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 A kind of adamantane and dimethylaminopyridine structural derivative, preparation method and the usage

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1363415A (en) * 1970-08-04 1974-08-14 Ici Ltd Bis-pyridyl amine compounds
JP2003515604A (en) * 1999-11-29 2003-05-07 アベンテイス・フアルマ・ソシエテ・アノニム Arylamine derivatives and their use as anti-telomerase agents

Also Published As

Publication number Publication date
CA2498281A1 (en) 2004-03-25
EP1546129A1 (en) 2005-06-29
AU2003260472A1 (en) 2004-04-30
WO2004024711A1 (en) 2004-03-25
JP2006503028A (en) 2006-01-26
MXPA05001883A (en) 2005-06-03

Similar Documents

Publication Publication Date Title
BR0314195A (en) Substituted Pyridine Derivatives as Antitumor Agents
BR0017030B8 (en) thiazolylamide derivatives, process for their preparation, pharmaceutical composition comprising them and their use
PA8551001A1 (en) NEW COMPOUNDS
BRPI0411900B8 (en) compounds and pharmaceutical compositions comprising them
BR122019010008B8 (en) pyrimidine derivatives, their use, and pharmaceutical composition and combination
BR0313160A (en) Compound, pharmaceutical composition, methods for treating a condition and a susceptible neoplasm in an animal in an animal, process for preparing a compound and use of a compound.
BR0108678A (en) New compounds
BR0214243A (en) Sulfonamide derivative Process for the preparation of a sulfonamide derivative and its physiologically acceptable salts, pharmaceutical composition and use of a sulfonamide derivative
UY27755A1 (en) NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS.
BR0316680A (en) Chk, pdk and akt inhibitor pyrimidines, their production and use as pharmaceutical agents
BR0315296A (en) Spirocyclic cyclohexanol derivatives
BR0313041A (en) Compounds; pharmaceutical compositions; method for the treatment and / or prophylaxis of diseases that are associated with cb1 receptor modulation; and use of compounds
BR122019010200B8 (en) pyrazole-quinazoline compounds, their salts, products or kits and pharmaceutical compositions
PT1119543E (en) N-ARALHYLAMINOTETRALINES AS LIGANDS FOR NEUROPEPTIDE AND Y5 RECEPTOR
UY27714A1 (en) 2 - HETEROARIL - CDK INHIBITING PYRIMIDINES, ITS PREPARATION AND ITS USE AS MEDICATIONS.
BRPI0514750A (en) 7-amino-3-phenyl-dihydropyrime [4,5-d] pyrimidinones amide derivatives, their manufacture and use as protein kinase inhibitors
SE9904505D0 (en) Novel compounds
BRPI0113146B8 (en) "proline derivatives and pharmaceutical composition comprising them".
CO5640037A2 (en) DERIVATIVES OF QUINAZOLINE FOR THE TREATMENT OF CANCER
BR0308429A (en) Monocyclic Aroylpyridinones as Anti-Inflammatory Agents
BRPI0415613A (en) novel diazaspiroalkane compounds and their use in the treatment of ccr8-mediated diseases
BRPI0108395B8 (en) pyrrolopyrimidinone derivatives, preparation and use processes
GT200300294A (en) INDAZOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINES AND PROCEDURES FOR USE
BRPI0512986A (en) new hydantoin derivatives
BRPI0413094A (en) quinoline derivatives and their use in therapy

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A,5A,6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.